# Major Recall Alert: Regpara Tab 25mg Recalled Due to Presence of N-nitroso-cinacalcet, a Probable Human Carcinogen
[Kyowa Kirin's Regpara Tab 25mg](https://nafdac.gov.ng/public-alert-no-12-2025-recall-of-batches-of-regpara-tablets-25mg-due-to-the-presence-of-impurity/) has officially been recalled in Nigeria due to the detection of N-nitroso-cinacalcet, an impurity that exceeds acceptable daily intake levels and is classified as a probable human carcinogen. This recall has raised significant public health concerns, and consumers and supply chain stakeholders are urged to act promptly.
Read on to understand what this recall means, the risks involved, and how you can protect yourself and others.
## Why This Recall is Important
This recall addresses a critical safety concern. N-nitroso-cinacalcet, the impurity found in Regpara Tab 25mg, belongs to a family of nitrosamines, which are compounds classified by regulatory authorities as probable human carcinogens. Extended exposure to higher-than-acceptable levels of such impurities may increase the risk of developing cancer over time. Recognizing these dangers, the National Agency for Food and Drug Administration and Control (NAFDAC) has issued a public alert to safeguard the health of Nigerians.
The recall emphasizes the necessity of strict quality control in pharmaceuticals, particularly for medications prescribed for critical conditions. Failing to address this issue can lead to harmful consequences for patients and deteriorates public trust in health products globally.
## Details of the Recall
Key information about the recall includes:
- **Product Name**: Regpara Tablet 25mg
- **Brand**: Kyowa Kirin
- **Reason for Recall**: Presence of the impurity, N-nitroso-cinacalcet, exceeding acceptable daily intake limits, posing carcinogenic risks.
- **Category**: Medication recall in Nigeria
- **Risk Classification**: Probable human carcinogen
- **Action Date**: Announced on 28705 by NAFDAC
- **Health Risks**: Long-term exposure may increase cancer risks.
Consumers, distributors, health workers, and all stakeholders are advised to immediately halt the use, distribution, and sale of this product. Any active possession of the recalled batches should be reported.
## What You Should Do
NAFDAC has issued clear instructions to manage the recall and mitigate risks:
- **Avoid Using the Recalled Product**: Do not administer or consume Regpara Tab 25mg.
- **Check for Authenticity**: Always source medical products from authorized/licensed suppliers.
- **Inspect Physical Condition**: Verify labels, seals, and expiry dates to detect any signs of tampering or substandard quality.
- **Report Issues**: If you suspect substandard products or experience adverse effects, immediately report to the nearest NAFDAC office or use their official reporting platforms.
For detailed guidance, access the official *Public Alert No. 12/2025* [here](https://nafdac.gov.ng/public-alert-no-12-2025-recall-of-batches-of-regpara-tablets-25mg-due-to-the-presence-of-impurity/).
## Stay Safe – Get Instant Recall Alerts
Keeping track of recall notifications is crucial to safeguarding yourself and your loved ones from potentially harmful products. Stay informed by subscribing to reliable platforms that provide real-time health alerts.
**Want immediate updates on product recalls?** Download the NAFDAC Consumer Safety App today! This user-friendly app will notify you about recalls, provide safety tips, and help you confirm the authenticity of products.
Stay vigilant, informed, and proactive in protecting public health from unsafe medications and counterfeit products. Help spread the word about this significant recall to prevent harm and ensure compliance.
**For the latest updates, visit NAFDAC online at [nafdac.gov.ng](https://nafdac.gov.ng).**